Atherosclerosis is the build up of fats, cholesterol and cellular waste in arterial walls and is a major factor in Heart Attacks and Stroke, the leading causes of death globally.
Corvida™ is in development to be a Best-in-Class, orally administered adjunct to statin therapy to treat atherosclerosis by targeting high-risk, vulnerable plaques.
Corvida™ significantly reduced arterial plaque in the ApoE-/- mouse model in a study conducted at The Cleveland Clinic:  Aortic Sinus lesion area reduced by 45%,
p< 0.001 and Aortic Lesion (%) reduced by 67%, p< 0.001 .